The new investment, Fujifilm said, will add eight 20,000 L mammalian cell culture bioreactors by 2028, to the already planned eight 20,000 L for bulk drug substance as part of the initial investment.

The company said that the new facility allows for flexibility to expand with additional bioreactors to accommodate new projects to meet the emerging needs of partners, and upon completion, it will make the site one of the largest cell culture biopharmaceutical CDMO facilities in North America.

According to Fujifilm Diosynth Biotechnologies, its modular production model called KojoXTM enables the company to construct identical large-scale production facilities in US and Europe to ensure a seamless integration of drug manufacturing production regardless of location.

"This investment is an important step to further accelerate the growth of our biopharmaceutical CDMO business,” said Teiichi Goto, Fujifilm’s president and CEO.

“We are pleased to continue investing to grow our cell culture manufacturing capabilities in North Carolina in anticipation of the growing outsourcing needs of biopharma companies,” said Toshihisa Iida, corporate vice president of Fujifilm and chairman of Fujifilm Diosynth Biotechnologies.

The expansion is expected to create 680 additional jobs by 2031, bringing the total number of new jobs in Holly Springs to 1,400.